NO regulatory agency has evaluated oral tirzepatide
But it also creates a challenge that is easy to underestimate
Without enough homocysteine, nerves are left vulnerable to damage, leading to symptoms such as tingling, numbness, and even chronic pain
On this point, Rinaman noted: Its not clear whether that is due to receptor desensitization or other compensatory mechanismseither neural, physiological, or behavioral. There is also limited data on how chronic treatment reshapes brain circuits
2007;293(2):F5215 Fung TT, Chiuve SE, McCullough ML, Rexrode KM, Logroscino G, Hu FB
Ipamorelin acts synergistically when applied during a native GHRH (growth-hormone releasing hormone) pulse or when coadministered with GHRH or a GHRH analog such as Sermorelin or GRF 1-29 (growth releasing factor, aminos 1-29).[1] The synergy comes both due to the suppression of somatostatin and the fact that ipamorelin increases GH release per-somatotrope, while GHRH increases the number of somatotropes releasing GH.[1,2] There is also a secondary effect of neuronal excitation in the hypothalamus caused by ipamorelin, which lasts for approximately 3 hours after application, similar to GHRP-2 and GHRP-6
